On January 17, Junshi Biosciences (688180.SH) announced that 1. According to the preliminary calculation of the financial department, it is expected that the annual operating income in 2024 will be about 1949000000 yuan, an increase of about 446.4501 million yuan compared with the same period of the previous year, a year-on-year increase of about 29.71%. 2. It is estimated that the annual R&D expenses in 2024 will be about 127,400.00 yuan, a decrease of about 663,469,500 yuan compared with the same period of the previous year, a year-on-year decrease of about 34.24%. 3. It is estimated that the net profit attributable to the owners of the parent company in 2024 will be about 1292.00 million yuan, a decrease of about 991.4319 million yuan compared with the same period of the previous year, and a year-on-year decrease of about 43.42%. 4. It is estimated that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2024 will be about 12730000000 yuan, a decrease of about 1024588000 yuan compared with the same period of the previous year, and a year-on-year decrease of about 44.59%.

The company's net profit attributable to the owners of the parent company in 2024 is still in the red, but the amount of loss is lower than that of the same period last year, mainly because the company actively implements the action plan of "improving quality and efficiency and emphasizing returns", continuously strengthens various cost control, reduces unit production costs, improves sales efficiency, and focuses resources on more potential R&D projects. During the reporting period, the company's R&D expenses are expected to be about 127,400.00 yuan, a decrease of about 34.24% compared with the same period last year. The company has maintained the efficient advancement of its core pipeline while controlling R&D expenses, and has made a number of progresses. During the Reporting Period, the NDA for the first-line treatment of advanced triple-negative breast cancer, the first-line treatment of advanced renal cell carcinoma and the first-line treatment of extensive-stage small cell lung cancer was approved by the National Medical Products Administration (NMPA), and the NDA for the first-line treatment of melanoma and bevacizumab for the first-line treatment of advanced hepatocellular carcinoma was accepted by the NMPA. Ongoliximab injection was approved for marketing by the State Food and Drug Administration. The company is accelerating the R&D and marketing application of late-stage pipelines such as anti-tumor anti-BTLA monoclonal antibody tifcemalimab (code: TAB004/JS004) and anti-IL-17A monoclonal antibody (code: JS005), and continues to explore including PD-1/VEGF bispecific antibody (code: JS207), Claudin18.2ADC drug (code: JS107), PI3K-α is an early-stage pipeline of oral small molecule inhibitors (code: JS105), CD20/CD3 bispecific antibodies (code: JS203), anti-DKK1 monoclonal antibody (code: JS015) and other products, and promotes more advantageous products and indications to enter the registration and clinical trial stage as soon as possible.